Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Dual Therapy With Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?

Headache The Journal of Head and Face Pain(2020)10.1111/head.13843Source: DataRank Database

Dual Therapy With Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale? is a research paper published in Headache The Journal of Head and Face Pain (2020). On theSindex it has a DataRank of 0. It has been cited 96 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

96 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 9.06)OA: closedTopics (34)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

P. Thien,Håkan Ashina ORCID,Messoud Ashina ORCID,Rami Burstein ORCID,Lanfranco Pellesi ORCID

Live enrichment

PubMed:32437038 OpenAlex:https://openalex.org/W3026778315

National Institutes of Health

Grant: R37‐NS079678

National Institutes of Health

Grant: R01‐NS094198

National Institutes of Health

Grant: R01‐ NS095655

NIH HHS

Grant: R01-NS094198

NIH HHS

Grant: R37-NS079678

Lundbeck Foundation

Grant: R155-2014-171

NIH HHS

Grant: R01- NS095655

Allergan

Teva Pharmaceutical Industries

FWCI

9.06

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

closedLicense: http://onlinelibrary.wiley.com/termsAndConditions#vor

publisherhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fhead.13843

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/head.13843

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1111/head.13843

publisherhttps://headachejournal.onlinelibrary.wiley.com/doi/pdf/10.1111/head.13843

journalhttps://doi.org/10.1111/head.13843

Fields of Study

Migraine and Headache StudiesBotulinum Toxin and Related Neurological DisordersUrinary Bladder and Prostate Research

MeSH Terms

AnimalsAntibodies, MonoclonalDrug SynergismDrug Therapy, CombinationHumansImmunologic FactorsMigraine DisordersNeuromuscular AgentsCalcitonin Gene-Related PeptideBotulinum Toxins, Type A

Keywords

Monoclonal antibodyMedicineCalcitonin gene-related peptideBotulinum toxinMigraineAntibodyToxinPharmacologyImmunologyInternal medicineAnesthesiaMicrobiologyBiologyReceptorNeuropeptideNeurotransmissionPainPathophysiologycombined therapyantagonismHeadache

Sustainable Development Goals

SDG 0: Good health and well-being